Year-End Review Post #4: Speaking at LSI Barcelona 2023 Honored to have been a part of LSI Barcelona 2023 in September 2023! It was exciting to share insights and our newly generated knowledge about single-shot-short-duration heart ablation as a speaker at this esteemed event. Grateful for the opportunity to contribute to the dialogue on Pulmonary Vein Isolation as first line therapy for atrial fibrillation (AFib), the leading cause for stroke. Today less than 5% of global patients suffering from atrial fibrillation are treated with heart ablations, the recommended first line therapy to treat atrial fibrillation. Let´s work together to make this essential treatment available to the 95% in need globally. This is a unique humanitarian and commercial chance and millions of patients and a multi-billion dollar market are ahead of us. Outstanding discussions and networking opportunity to exchange thoughts and connect with industry leaders. #AQUAHeart #LSIEurope23 #Speaker #IndustryInsights #afib #pvi #cardiovascular #venturecapital #medicaldevices #stroke #strokeprevention #heartablation
Holger Friedrich’s Post
More Relevant Posts
-
𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study 👉 𝟏𝟎𝟗 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟐 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpital Paris Saint-Joseph BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik
-
-
Exciting news today as Biosense Webster receives European CE mark approval for our VARIPULSE™ Platform, marking a significant step forward in treating cardiac arrhythmia with pulsed field ablation (PFA) technology. With estimates suggesting that by 2050, Europe will have the greatest increase in Atrial Fibrillation compared to other regions globally, this milestone not only signifies our commitment to innovation in cardiac care but also positions us here in Europe at the forefront of solving some of the most pressing challenges in cardiac care. Our focus now is working alongside physicians and healthcare providers, together with our leading clinical teams throughout the region to bring this technology to all those patients who can benefit. https://lnkd.in/edYARrJz #myCompany #CardiacCare #JNJMedTechProud #VARIPULSE #PulsedFieldAblation
-
-
𝐁𝐈𝐎-𝐎𝐒𝐂𝐀𝐑 𝐒𝐎𝐂 𝐒𝐓𝐔𝐃𝐘 : A prospective, multicenter, observational study evaluating standard of care practices, procedural outcomes, and in-hospital complications of endovascular procedures for treatment of atherosclerotic lesions in the infrainguinal arteries. 🔄 Update on the status of the BIO-OSCAR SOC study 👉 𝟏𝟔𝟐 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐬 𝐞𝐧𝐫𝐨𝐥𝐥𝐞𝐝 𝐰𝐢𝐭𝐡 𝟏𝟐 𝐬𝐢𝐭𝐞𝐬 𝐨𝐩𝐞𝐧 𝐟𝐨𝐫 𝐞𝐧𝐫𝐨𝐥𝐦𝐞𝐧𝐭 Hôpitaux Saint-Joseph & Marie-Lannelongue BIOTRONIK #biooscarstudy #biooscarsoc #observationalstudy #endovascular #treatment #atherosclerotic #atheroscleroticlesions #infrainguinalarteries #clinicalstrial #groupehospitalierparissaintjoseph #hopitalparissaintjoseph #biotronik
-
-
Automatic, objective, daily remote monitoring powers BIOTRONIK Neuro’s one-of-a-kind proactive care. What does that mean for SCS patients? Join us at #ASPN2024 for “Unparalleled Proactive Care: Clinical Evidence for Prospera™”. At this lunch symposium, we’ll explore the data driving BIOTRONIK Neuro’s spinal cord stimulation (SCS) innovation—the Prospera SCS System with Embrace One™. Register today: https://ow.ly/aGW450SpvBr #BIOTRONIKNeuro
-
-
Medical Director at: New England Stem Cell Institute; Valley Sports Physicians & Orthopedic Medicine
DeQuervain's Tenosynovitis New patient seen today for evaluation of 2-year history of chronic right radial styloid pain. Exam and US are consistent with DeQuervain's. US imaging shows significantly enlarged APL and EPB tendons in the affected right side, especially when compared to the uninvolved left side. NOTE: The APL exists in multiple bundles in 80% of normal people! So be careful about making a diagnosis based solely on US imaging. For my diagnostic and interventional instructional MSK US videos, go to www.UltrasoundDocs.com! #deQuervain #DeQuervains #tenosynovitis #wristpain #US #EPB #APL
-
-
Dr Perez de Prado's clinical case highlights the relevance of Angiolite's remarkable overexpansion capability. In cases of distal left main or aneurysmatic arteries, the significance of a stent with high overexpansion capacity cannot be overstated. Explore the complete clinical case ➡️ https://lnkd.in/eSSX6aaV #Angiolite #OverexpansionCapability #CoronaryDisease #ClinicalCase
-
A new study in the Journal of Trauma and Injury has developed a predictive nomogram-based model for lower extremity compartment syndrome (ACS) after trauma. Utilising the TQIP database, researchers identified novel risk factors such as venous thromboembolism (VTE) prophylaxis type and blood product transfusions. Key Findings: ▪️ VTE Prophylaxis Type: Unfractionated heparin increases #ACS risk (OR 2.67; 95% CI 2.33–3.05) ▪️ #BloodTransfusions: Each unit of blood increases ACS risk (OR 1.13; 95% CI 1.09–1.18) ▪️ Study Size: 2,629 ACS cases vs. 762,083 controls At Softcell Medical, we understand the critical need for #earlydetection in managing ACS. Our SentinelpH® technology aims to provide real-time cellular pH monitoring, helping to identify tissue #ischaemia early and potentially prevent ACS progression. By supporting predictive models our technology will seek to enhance clinical decision-making and improving patient outcomes. #MedicalResearch #TraumaCare #CompartmentSyndrome #HealthcareInnovation #SentinelpH #Medtech #MedicalInnovation
-
New late breaking #Medtronic #SMARTtrial 1 yr outcomes at #ACC2024 confirms why I think #EvolutFirst in #TAVR. This data is the latest in a growing body of evidence that highlights our commitment to world class clinical trials. Ready to learn more? Let’s talk! #medtronicemployee. #structuralheart #aorticstenosis #VCC
SVP and President, Structural Heart & Aortic at Medtronic ✦ Board Member ✦ Growth Acceleration ✦ MedTech Innovation ✦ DEI
Neil Yanke and I are thrilled to share the highly anticipated results of the SMART Trial at the American College of Cardiology’s annual scientific session. The one-year data from the SMART Trial demonstrates that Evolut #TAVR delivers superior valve performance versus SAPIEN 3, with excellent short-term outcomes in small annulus patients, including women¹. Importantly, these early results suggest that when women have access to the treatment they need to address their aortic stenosis, they can thrive – particularly when treated with an Evolut valve. We are incredibly excited about what these results mean for our physician partners treating small annuli patients, including women. Thank you and congratulations to our talented team across Medtronic Structural Heart, our investigators and clinicians, trial sites, and all involved on this significant milestone! #MedtronicEmployee ¹Herrmann HC, Mehran R, Blackman, DJ, et al. Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus. N Engl J Med 2024; DOI: 10.1056/NEJMoa2312573; published online April 7, 2024 Risk info: https://lnkd.in/e9BGNCZi
-
Exciting news from Biosplice! We're participating in the World Congress of Osteoarthritis (WCO) 2024, taking place from April 11th to 15th in London, UK. At this year's conference, we're excited to present our latest research findings: 🔹 Oral Presentation: "Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections Over 3 Years in Subjects with Severe Knee Osteoarthritis." 🔹 Oral Poster Presentation P674: "Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial." These presentations highlight our ongoing commitment to advancing the treatment landscape for osteoarthritis and working to improve patient outcomes. #WCO2024 #Biosplice #London
-
-
Every three seconds, someone somewhere in the world is affected by a stroke, and according to the World Stroke Organization, 101 million people are living with the aftermath of a stroke. For an optimized stroke treatment and a good patient outcome, time is of the essence. Healthcare practitioners aim to set up the ideal pathway for fast diagnosis and treatment of their patients. A well-coordinated treatment pathway is essential for optimal care and prevention to reduce the recurrence rate. Imaging technologies assist in a wide range of stroke scenarios identifying conditions such as blood clots, carotid plaques or a vessel ruptures, while our ARTIS icono therapy device plays a key role in supporting the continuum of care through endovascular treatment. Explore our integrated stroke solutions to see how to streamline a stroke workflow to overcome possible constraints. 🎥 Watch our informative video now! https://lnkd.in/d7vFhSBJ #StrokeCare #HealthcareInnovation #SiemensHealthineers
When stroke strikes, be ahead of your time.
siemens-healthineers.com
